Literature DB >> 2861072

Beta-blockers and glucose control.

G A Mills, J R Horn.   

Abstract

Literature on the effects of beta-blockers on blood glucose is reviewed. Data are presented regarding the adrenergic influences on glucose regulation and the effects of beta-blockade during hypo- and hyperglycemia in normal and diabetic individuals. beta-adrenergic stimulation enhances insulin and glucagon secretion, as well as glycogenolysis, gluconeogenesis, and lipolysis. alpha-adrenergic stimulation inhibits insulin secretion and may inhibit glucagon secretion and enhance liver glycogenolysis. In nondiabetics, beta-blockers represent minimal risk of affecting glucose control. In insulin-dependent diabetics, beta-blockers can prolong, enhance, or alter the symptoms of hypoglycemia, while hyperglycemia appears to be the major risk in noninsulin-dependent diabetics. beta-blockers can potentially increase blood glucose concentrations and antagonize the action of oral hypoglycemic drugs.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2861072     DOI: 10.1177/106002808501900401

Source DB:  PubMed          Journal:  Drug Intell Clin Pharm        ISSN: 0012-6578


  4 in total

1.  Modulation of the effects of salbutamol by propranolol and atenolol.

Authors:  N A Minton; A R Baird; J A Henry
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

Review 2.  Formulary considerations in selection of beta-blockers.

Authors:  K C Yedinak
Journal:  Pharmacoeconomics       Date:  1993-08       Impact factor: 4.981

Review 3.  Beta-blockers after acute myocardial infarction in elderly patients with diabetes mellitus: time to reassess.

Authors:  Mauro Di Bari; Niccolò Marchionni; Marco Pahor
Journal:  Drugs Aging       Date:  2003       Impact factor: 3.923

4.  Primary care experience and remission of type 2 diabetes: a population-based prospective cohort study.

Authors:  Hajira Dambha-Miller; Alexander Day; Ann Louise Kinmonth; Simon J Griffin
Journal:  Fam Pract       Date:  2021-03-29       Impact factor: 2.267

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.